Trial · NCT07912710
China HEalthy Aging and Dementia Study (HEAD)
NCT07912710, Recruiting, Fudan University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. China HEalthy Aging and Dementia Study (HEAD). Trials, record NCT07912710. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07912710
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- China HEalthy Aging and Dementia Study (HEAD)
- NCT number
- NCT07912710
- Status
- Recruiting
- Enrollment
- 20,000 participants, estimated
- Lead sponsor
- Fudan University
- Conditions
- Alzheimer Disease (AD), Mild Cognitive Impairment (MCI), Dementia, Vascular Dementia (VaD), Cognitive Decline, Familial Alzheimer Disease (FAD), Non-Alzheimer Degenerative Dementia
- First posted
- 2026-11-03
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes34
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mild cognitive impairment (MCI) | Baseline and approximately annual follow-up assessments (up to 50 years) | MCI is diagnosed according to the 2004 International Working Group (IWG) broad clinical criteria. Diagnostic status is assessed at baseline and during follow-up. |
| Primary | Dementia | Baseline and approximately annual follow-up assessments (up to 50 years) | Dementia is diagnosed according to the 2011 National Institute on Aging-Alzheimer's Association (NIA-AA) core clinical criteria for all-cause dementia. Diagnostic status is assessed at baseline and during follow-up. |
| Primary | Mild cognitive impairment due to Alzheimer's disease (MCI due to AD) | Baseline and approximately annual follow-up assessments (up to 50 years) | MCI due to AD is diagnosed according to the 2011 NIA-AA clinical criteria, based on the presence of MCI and clinical evidence consistent with AD etiology. Diagnostic status is assessed at baseline and during follow-up. |
| Primary | Dementia due to Alzheimer's disease (AD dementia) | Baseline and approximately annual follow-up assessments (up to 50 years) | AD dementia is diagnosed according to the 2011 NIA-AA clinical criteria for probable or possible Alzheimer's disease dementia among participants meeting the criteria for all-cause dementia. Diagnostic status is assessed at baseline and during follow-up. |
| Primary | Mini-Mental State Examination (MMSE) total score | Baseline and approximately annual follow-up assessments (up to 50 years) | Global cognitive function is assessed using the MMSE (range: 0-30; higher scores indicate better cognition). Longitudinal changes are used to evaluate the rate of cognitive decline. |
| Primary | Montreal Cognitive Assessment (MoCA) total score | Baseline and approximately annual follow-up assessments (up to 50 years) | Global cognitive function is assessed using the MoCA (range: 0-30; higher scores indicate better cognition). Longitudinal changes are used to evaluate the rate of cognitive decline. |
| Primary | Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score | Baseline and approximately annual follow-up assessments (up to 50 years) | Cognitive and functional impairment is assessed using CDR-SB (range: 0-18; higher scores indicate greater impairment). Longitudinal changes are used to evaluate the rate of decline. |
| Secondary | Auditory Verbal Learning Test (AVLT) learning score | Baseline and approximately annual follow-up assessments (up to 50 years) | Verbal learning is assessed using the sum of correctly recalled words across AVLT learning trials N1-N3. Higher scores indicate better performance. Longitudinal changes are evaluated using repeated assessments. |
| Secondary | Auditory Verbal Learning Test (AVLT) short-delay recall score | Baseline and approximately annual follow-up assessments (up to 50 years) | Short-delay memory is assessed using the number of correctly recalled words in AVLT N4. Higher scores indicate better memory performance. Longitudinal changes are evaluated using repeated assessments. |
| Secondary | Auditory Verbal Learning Test (AVLT) long-delay recall score | Baseline and approximately annual follow-up assessments (up to 50 years) | Long-delay memory is assessed using the number of correctly recalled words in AVLT N5. Higher scores indicate better memory performance. Longitudinal changes are evaluated using repeated assessments. |
1 to 10 of 34Source ClinicalTrials.gov
See all 34 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests6
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Clock Drawing Task | Secondary outcome | ConductCognition |
| Digit Span Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Fluency | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07912710
GET https://conductscience.org/api/trials/v1/NCT07912710/registered?page=2